Three-drug therapy for advanced KRAS-mutant lung cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs for lung cancer with a KRAS mutation. The drugs may shrink or slow the cancer, and one of them helps your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or stage IV non-small cell lung cancer that cannot be removed with surgery.
- Your cancer has a specific change called a KRAS mutation.
- You have had one standard treatment for your cancer, and it has stopped working.
- You have no active brain metastases.
- You are between 18 and 75 years old.
- You are in fairly good health and can care for yourself (ECOG score 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs (luvometinib and anlotinib) together to treat advanced lung cancer that has a KRAS mutation and has grown despite previous treatment. The goal is to see if this combination helps patients live longer and slows cancer growth.
This trial tests an experimental drug called LT-010391 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The drug is designed to target this mutation, and the study aims to see if it can help when standard treatments are no longer working.
This study tests a combination of two targeted therapy pills (andamertinib and anlotinib) for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has progressed after taking a previous targeted therapy. The goal is to see if this new combination can stop the cancer from growing.
This trial tests whether adding the immunotherapy drug tislelizumab before and after surgery can help people with a specific type of lung cancer (non-squamous NSCLC with a KRAS mutation) that is stage 2 or 3. It aims to improve treatment outcomes by targeting the cancer early.
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
This trial tests a combination of two targeted drugs, imatinib and trametinib, for people with advanced solid tumors that have a specific KRAS mutation (G12X). It may be an option if standard treatments have stopped working or are not available.
Hear when a new KRAS Mutation-Related Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.